Cancer Drug Prices Surge Amid Shortage
In a harrowing turn of events for cancer patients across Sri Lanka, reports have emerged indicating that a crucial medication designed to safeguard them from infections is now being sold on the black market for over Rs. 25,000—a staggering increase from its original price of approximately Rs. 900. This surge in pricing stems from a severe supply shortage, as highlighted by the Doctors’ Trade Union Alliance for Medical and Civil Rights.
Dr. Chamal Sanjeewa, Chairman of the Trade Union Alliance, revealed that the medication, available under brand names such as Neup, Neupogen, GCadF, and Filgrastim, is indispensable for those undergoing treatments like chemotherapy. It stimulates the production of white blood cells, thereby fortifying patients’ immune systems during a precarious time in their health journey.
Supply Crisis Details
The dire shortage of this essential drug has forced many cancer patients, including children, to seek supplies through unofficial channels, sometimes at exorbitant prices exceeding Rs. 25,000. “Even at these inflated costs, the medication is remarkably difficult to locate,” Dr. Sanjeewa lamented. He attributed the crisis to a bureaucratic impasse involving an imported consignment that has been stalled in warehouses due to labeling disputes with the Medical Supplies Division.
According to Dr. Sanjeewa, as nearly 100,000 units of the medication remain undelivered, approximately 25,000 patients who rely on the medicine monthly stand to be affected. The ripple effect could mean that over 75,000 patients may struggle to access this life-saving drug if the shortage persists unabated.
Calls for Immediate Action
Amplified frustrations around the shortage have led experts like Dr. Sanjeewa to plead for intervention by key health authorities, including the Ministry of Health and the National Cancer Institute. He stressed the importance of resolving logistical and regulatory hurdles swiftly to restore access to vital medicines. “Administrative and regulatory issues must not obstruct the life-saving treatment cancer patients desperately need,” he argued.
Additionally, Dr. Sanjeewa pointed out the concerning reality that numerous other cancer medications are also in limited supply, impacting both public and private healthcare facilities. The repercussions of this ongoing issue are far-reaching, placing not only a financial strain on patients and their families but also endangering their health during a critical period.
As calls for action resonate within medical and public fora alike, the hope remains that authorities will take expedient measures to address these challenges and reestablish a steady flow of essential medications to those in need. An impending evaluation and release of existing stocks are crucial to avert further tragedies in the ongoing battle against cancer.